This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Maze Therapeutics, Inc.. Active years: 2024-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2025
Title: Todd Jonathan August Ewing: Innovator in APOL1 Inhibitors
Introduction
Todd Jonathan August Ewing is a notable inventor based in Walnut Creek, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of APOL1 inhibitors. With a total of 2 patents, Ewing's work is paving the way for advancements in treating APOL1-mediated diseases.
Latest Patents
Ewing's latest patents focus on APOL1 inhibitors and methods of use. The patents detail compounds of formula (II), which include stereoisomers, tautomers, and pharmaceutically acceptable salts. These compounds are designed to inhibit APOL1 and provide methods for treating various diseases, disorders, or conditions associated with APOL1.
Career Highlights
Ewing is currently associated with Maze Therapeutics, Inc., where he continues to innovate in the pharmaceutical sector. His work is crucial in addressing health issues related to APOL1, showcasing his commitment to improving patient outcomes through scientific research.
Collaborations
Ewing collaborates with talented individuals such as Patrick Sang Tae Lee and Adam Neil Reid. Their combined expertise enhances the research and development efforts at Maze Therapeutics, Inc.
Conclusion
Todd Jonathan August Ewing is a prominent figure in the field of pharmaceutical innovation, particularly in the area of APOL1 inhibitors. His contributions are vital for the advancement of treatments for APOL1-mediated conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile